Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma
Authors:
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (2) , 246-257
Abstract
No abstract availableKeywords
Funding Information
- PROSPECT (W81XWH-07-1-0306)
- PS30 Cancer Center (P30 CA016672)
This publication has 45 references indexed in Scilit:
- Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2009
- Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and resultsLung Cancer, 2007
- Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesotheliomaAnnals of Oncology, 2007
- Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II TrialJournal of Thoracic Oncology, 2006
- Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2004
- Basis and Importance of SRC as a Target in Cancer2004
- Epithelial–mesenchymal transitions in tumour progressionNature Reviews Cancer, 2002
- Role of Src expression and activation in human cancerOncogene, 2000
- Activating SRC mutation in a subset of advanced human colon cancersNature Genetics, 1999
- The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells.Proceedings of the National Academy of Sciences, 1993